Display options
Share it on

Open Access Rheumatol. 2020 Aug 24;12:175-185. doi: 10.2147/OARRR.S257470. eCollection 2020.

Mitochondrial Imbalance as a New Approach to the Study of Fibromyalgia.

Open access rheumatology : research and reviews

Antonio Martínez-Lara, Ana María Moreno-Fernández, Maripaz Jiménez-Guerrero, Claudia Díaz-López, Manuel De-Miguel, David Cotán, José Antonio Sánchez-Alcázar

Affiliations

  1. Pronacera Therapeutics S.L., Seville, Spain.
  2. Departamento de Citología e Histología Normal y Patológica, Facultad de Medicina, Universidad de Sevilla, Seville, Spain.
  3. Centro Andaluz de Biología del Desarrollo (CABD-CSIC-Universidad Pablo de Olavide), Seville 41013, Spain.

PMID: 32922097 PMCID: PMC7455536 DOI: 10.2147/OARRR.S257470

Abstract

BACKGROUND: Fibromyalgia (FM) is a common chronic pain disease, whose pathogenic mechanism still remains elusive. Oxidative stress markers and impaired bioenergetics homeostasis have been proposed as relevant events in the pathogenesis of the disease. Hence, the aim of the study is to analyse the potential biomarkers of mitochondrial imbalance in FM patients along with coenzyme Q10 (CoQ10) as a possible treatment.

METHODS: The symptomatology of patients was recorded with an adaption of the Fibromyalgia Impact Questionnaire (FIQ). Mitochondrial imbalance was tested from blood extraction and serum isolation in 33 patients diagnosed with FM and 30 healthy controls. Western blot and HPLC techniques were performed to study the different parameters. Finally, bioinformatic analysis of machine learning was performed to predict possible associations of results.

RESULTS: CoQ10 parameter did not show evidence to be a good marker of the disease, as the values are not significantly different between control and patient groups (Student's

CONCLUSION: Our study supports the hypothesis that an imbalance in mitochondrial homeostasis is involved in the FM pathogenesis. However, whether the increase in oxidative stress is the result of mitochondrial imbalance or the cause of this disease remains an open question. The measurement of this imbalance might be used as a preliminary biomarker for the diagnosis and follow-up of patients with FM, and even for the evaluation of the effects of the different antioxidants therapies.

© 2020 Martínez-Lara et al.

Keywords: chronic pain; diagnosis; fibromyalgia; mitochondria

Conflict of interest statement

Antonio Martínez-Lara, Maripaz Jiménez-Guerrero, Claudia Díaz-López, and David Cotán are employees of Pronacera Therapeutics S.L. The authors report no other potential conflicts of interest for this w

References

  1. Rheumatol Int. 2006 May;26(7):585-97 - PubMed
  2. Nat Rev Mol Cell Biol. 2011 Jan;12(1):9-14 - PubMed
  3. Curr Rheumatol Rep. 2017 Jan;19(1):5 - PubMed
  4. Mitochondrion. 2011 Jul;11(4):623-5 - PubMed
  5. Biochim Biophys Acta. 2004 Jan 28;1660(1-2):171-99 - PubMed
  6. Arthritis Rheum. 1990 Feb;33(2):160-72 - PubMed
  7. Int J Biochem Cell Biol. 2015 Jun;63:21-4 - PubMed
  8. Arthritis Res Ther. 2010;12(1):R17 - PubMed
  9. Arthritis Care Res (Hoboken). 2010 May;62(5):600-10 - PubMed
  10. PLoS Biol. 2010 Jan 26;8(1):e1000298 - PubMed
  11. Brain Res. 2011 Jun 7;1394:1-13 - PubMed
  12. Transl Res. 2010 Jul;156(1):15-25 - PubMed
  13. Blood. 2012 Jun 14;119(24):5859-70 - PubMed
  14. Exp Mol Pathol. 2007 Aug;83(1):84-92 - PubMed
  15. Pain. 2017 Jan;158(1):34-47 - PubMed
  16. Semin Arthritis Rheum. 2016 Dec;46(3):319-329 - PubMed
  17. Autophagy. 2011 Dec;7(12):1559-61 - PubMed
  18. Clin Biochem. 2009 May;42(7-8):732-5 - PubMed
  19. Biosystems. 2018 Mar;165:22-30 - PubMed
  20. FASEB J. 2011 Aug;25(8):2669-87 - PubMed
  21. Autophagy. 2009 Jan;5(1):19-32 - PubMed

Publication Types